| Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis A Khalvandi, M Abolhasani, Z Madjd, L Sharifi, P Bakhshi, ... World Journal of Urology 39, 1831-1843, 2021 | 4 | 2021 |
| Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy P Bakhshi, M Nourizadeh, L Sharifi, MM Farajollahi, M Mohsenzadegan Cancer Cell International 23 (1), 270, 2023 | 3 | 2023 |
| Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host N Kheshtchin, P Bakhshi, S Arab, M Nourizadeh International immunopharmacology 105, 108531, 2022 | 2 | 2022 |
| Sex-specific outcomes in cancer therapy: the central role of hormones P Bakhshi, JQ Ho, S Zanganeh Frontiers in Medical Technology 6, 1320690, 2024 | 1 | 2024 |
| Impaired monocyte‐derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors P Bakhshi, M Nourizadeh, L Sharifi, MR Nowroozi, M Mohsenzadegan, ... Cancer Reports 7 (2), e1996, 2024 | | 2024 |
| Evaluating the Effect of Protein A Signal Peptide on Extracellular Expression of Recombinant Hirudin in E. Coli P Bakhshi, M Saidijam, D Shahbazzadeh, N Mohajerani, H Mirzahoseini Medical Laboratory Journal 9 (5), 9-15, 2015 | | 2015 |
